Tenax Therapeutics announced that the United States Patent and Trademark Office, USPTO, has granted the Company a patent covering the use of TNX-103, TNX-102, TNX-101, the active metabolites of levosimendan and various combinations of cardiovascular drugs with levosimendan when used to improve exercise performance in PH-HFpEF patients, entitled: “LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION.” “Expanding our intellectual property estate for levosimendan is a strategic priority for Tenax. We are committed to protecting the future commercial value of our innovative PH-HFpEF treatment,” said Chris Giordano, President & Chief Executive Officer of Tenax Therapeutics. “The important, additional IP protection this patent provides will help us maximize the value of levosimendan as we seek to address one of the largest unmet needs in cardiovascular medicine today.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TENX:
- Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
- Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
- Tenax Therapeutics to Present at the 36th Annual Roth Conference
- Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
